BIOMAT Database Logo BIOMAT Database Logo

Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin. 1989

G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Department of Medicine, Indiana University School of Medicine, Indianapolis 46223.

The impact of tiazofurin on inhibition of IMP dehydrogenase was discussed at the clinical and molecular levels. 1. Evidence was provided for the role of IMP dehydrogenase and guanylates in the expression of the neoplastic program in cancer cells with particular relevance to human leukemic cells. 2. The argument for expecting an impact of tiazofurin in human myelocytic cells was provided. 3. Similarity of the kinetics of human leukemic cell IMP dehydrogenase to the rat hepatoma enzyme was documented. 4. New evidence was provided for the role of salvage in chemotherapy and the function of hypoxanthine in inhibiting guanine salvage. 5. The action of tiazofurin and retinoic acid was reported in HL-60 leukemic cells. 6. The effect of tiazofurin and retinoic acid on proliferation and cytotoxicity was outlined for hepatoma 3924A cells. 7. The effect of guanine on induced differentiation by tiazofurin and retinoic acid was examined. 8. Biochemical basis was provided for the lack of development of resistance in patients treated with tiazofurin. 9. Presumptive evidence was provided that tiazofurin treatment induced differentiation of leukemic cells in the patients. 10. The molecular biology of tiazofurin-induced differentiation in K-562 cells was reviewed with the possible relevance to clinical treatment that tiazofurin might also act through down-regulation of ras oncogene.

UI MeSH Term Description Entries
D007168 IMP Dehydrogenase An enzyme that catalyzes the dehydrogenation of inosine 5'-phosphate to xanthosine 5'-phosphate in the presence of NAD. EC 1.1.1.205. Inosinic Acid Dehydrogenase,Inosine-5-Monophosphate Dehydrogenase,Acid Dehydrogenase, Inosinic,Dehydrogenase, IMP,Dehydrogenase, Inosine-5-Monophosphate,Dehydrogenase, Inosinic Acid,Inosine 5 Monophosphate Dehydrogenase
D007658 Ketone Oxidoreductases Oxidoreductases that are specific for KETONES. Oxidoreductases, Ketone
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006151 Guanosine A purine nucleoside that has guanine linked by its N9 nitrogen to the C1 carbon of ribose. It is a component of ribonucleic acid and its nucleotides play important roles in metabolism. (From Dorland, 28th ed)
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites

Related Publications

G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
October 1992, Gynecologic oncology,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
January 1992, Life sciences,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
April 1984, The Journal of biological chemistry,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
February 1997, Cytometry,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.
March 1988, Biochemistry,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
January 1996, Anticancer research,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
December 1985, Molecular pharmacology,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
IMP dehydrogenase: structure, mechanism, and inhibition.
July 2009, Chemical reviews,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
IMP dehydrogenase: mechanism of action and inhibition.
July 1999, Current medicinal chemistry,
G Weber, and Y Yamaji, and E Olah, and Y Natsumeda, and H N Jayaram, and E Lapis, and W N Zhen, and N Prajda, and R Hoffman, and G J Tricot
Tiazofurin: molecular and clinical action.
January 1996, Anticancer research,
Copied contents to your clipboard!